Talphera (NASDAQ:TLPH) Shares Down 0.3% – Time to Sell?

Talphera, Inc. (NASDAQ:TLPH)’s share price traded down 0.3% during mid-day trading on Thursday . The stock traded as low as $0.7808 and last traded at $0.8079. 39,878 shares were traded during trading, a decline of 77% from the average session volume of 173,561 shares. The stock had previously closed at $0.81.

Analyst Ratings Changes

TLPH has been the topic of several recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Talphera in a research report on Wednesday, January 21st. Wall Street Zen upgraded shares of Talphera to a “hold” rating in a research note on Saturday, November 1st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $6.00.

Talphera Trading Down 0.3%

The stock has a market capitalization of $37.66 million, a price-to-earnings ratio of -2.13 and a beta of 0.46. The company has a fifty day moving average of $1.01 and a two-hundred day moving average of $0.98.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Group One Trading LLC lifted its position in Talphera by 3,224.0% during the 3rd quarter. Group One Trading LLC now owns 30,415 shares of the company’s stock worth $27,000 after acquiring an additional 29,500 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Talphera during the 3rd quarter worth about $29,000. Persistent Asset Partners Ltd acquired a new position in shares of Talphera during the 4th quarter worth about $42,000. Mariner LLC boosted its stake in Talphera by 132.0% during the 4th quarter. Mariner LLC now owns 58,000 shares of the company’s stock valued at $66,000 after purchasing an additional 33,000 shares during the period. Finally, Dauntless Investment Group LLC acquired a new stake in Talphera in the 3rd quarter valued at approximately $89,000. Institutional investors own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.